Quantcast
Connect with us

Here’s what Big Pharma fears the most about the November midterms

Published

on

The pharmaceutical lobby is showing its hand in the leadup to the 2018 midterm elections.

The New York Times reported that Big Pharma’s biggest fear is that Donald Trump will team up with Democrats to throttle drug prices.

“As the midterm elections approach, a feeling of foreboding has settled over the pharmaceutical industry,” John E. McManus, a GOP healthcare lobbyist who works with major drug companies, told the Times.

“Combine the rising blue wave — the Democrat fixation on pharmaceutical pricing — with President Trump’s populist focus on getting credit for cutting patients’ drug costs,” McManus added, “and the industry could be confronting a perfect storm in 2019.”

The report noted that if Democrats gain a majority in the House of Representatives, the Health Subcommittee on the powerful Ways and Means Committee will be under the power of Rep. Lloyd Doggett (D-TX), “an unyielding critic of what he calls price gouging by pharmaceutical companies.”

ADVERTISEMENT

Drug companies are reportedly counting on the Senate “to stop legislation they oppose,” the Times noted — but their comfortable relationship is soon to change.

With the loss of Finance Committee pharma defender Sen. Orrin Hatch (R-UT) and his likely succession by the more-populist Chuck Grassley (R-IA) — a supporter of importing drugs from Canada — the industry may not have enjoy the control they had in the upper chamber.

Read the entire report via the Times.

ADVERTISEMENT


Report typos and corrections to [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

Kim Jong-un threatens to restart nuke tests as Trump’s efforts to talk to the regime fall apart again: report

Published

on

On Tuesday, CNN's Brian Todd reported that the North Korean regime is on the brink of rescinding what little they promised President Donald Trump, as the future of his efforts to continue talks appear uncertain.

"Kim Jong-un's regime is once again in negotiation by intimidation," said Todd. "Just two weeks after their historic meeting at the DMZ, and President Trump's short stroll into North Korea, North Korea's dictator Kim Jong-un appears to be threatening to start testing his nuclear weapons again. In a new statement, Kim's foreign ministry calls the joint U.S./South Korean military exercises planned for next month a breach of the main spirit of what President Trump and Kim agreed to in Singapore, and says, 'We are gradually losing our justifications to follow through on the commitments we made with the U.S."

Continue Reading

Breaking Banner

‘He’s ignorant — not stupid’: NYT columnist says Trump is trying to ‘bait’ Democrats because he wants to run against AOC

Published

on

President Donald Trump is not going to get the 2020 opponent he wants, so he's going to pretend that his actual opposition is being led by the four young women in Congress known as The Squad, New York Times columnist Frank Bruni wrote on Tuesday.

Trump has spent the last few days with racist attacks on the four first-term members, who are Representatives Alexandria Ocasio-Cortez (D-NY), Ilhan Omar (D-MN), Ayanna Pressley (D-MA) and Rashida Tlaib (D-MI).

Continue Reading
 

Breaking Banner

‘Nickel and Dimed’ for the sharing economy: Inside the hellish new reality of low-wage work

Published

on

In 2001, journalist Barbara Ehrenreich's investigative book "Nickel and Dimed" revealed to those who weren't on low-wage payrolls how expensive it is to be a member of the working poor in America. Some things haven't changed since Ehrenreich's experiences working as a Walmart clerk, a restaurant server and a maid, among other jobs. Housing can still be prohibitively expensive on low hourly wages, and high turnover remains a constant. Workers still risk their health — mental, physical and emotional — every precarious day.

Continue Reading
 
 
 

Copyright © 2019 Raw Story Media, Inc. PO Box 21050, Washington, D.C. 20009 | Masthead | Privacy Policy | For corrections or concerns, please email [email protected]

close-image